Motor Neurone Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are a member of a family where at least one person has a known gene change linked to a condition called familial frontotemporal lobar degeneration (FTLD), specifically in genes called MAPT, GRN, C9orf72, or other rare related genes
• People from a family where multiple members across generations have been diagnosed with an FTLD-type condition, even if no specific gene change has been identified, confirmed through medical records or detailed family history
• People who have been diagnosed with a sporadic (non-inherited) form of FTLD — meaning they have symptoms but no known family history or gene change — and whose diagnosis falls into one of these categories: Progressive Supranuclear Palsy (PSP), Semantic variant Primary Progressive Aphasia, Nonfluent variant Primary Progressive Aphasia, Corticobasal Degeneration or Syndrome, Behavioral variant Frontotemporal Dementia, or Frontotemporal Dementia with ALS
• People joining the blood and fluid testing part of the trial may have either a familial or sporadic form of FTLD, and may be included regardless of their primary language, provided a translated consent form is available

Who may not be able to join:

• People who have a known structural problem in the brain, such as a tumour or a stroke-related injury, that could explain their symptoms
• People who carry a gene change known to cause Alzheimer's disease (in genes called PSEN1, PSEN2, or APP), or whose test results suggest Alzheimer's disease is the cause of their symptoms
• People with a history of a brain condition caused by severe alcohol use (called Korsakoff encephalopathy), serious alcohol dependence within 5 years of when symptoms began, frequent intoxication from alcohol or other substances, or another existing neurological condition
• People whose test results show uncorrected vitamin B12 deficiency, poorly controlled thyroid problems, HIV, kidney failure, liver failure, or a breathing condition requiring supplemental oxygen; or people with significant areas of damage to the brain's white matter, or serious ongoing illnesses such as worsening heart disease
• People currently taking a medication that, in the opinion of the trial doctor, is likely to significantly affect how the brain functions
• People who, in the trial doctor's opinion, are unable to complete enough of the required study tasks — though the trial site may still consider them for the blood and fluid testing part of the trial if they are able to tolerate a blood draw and a short clinical examination (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.